Drugs / Ozuriftamab Vedotin
Ozuriftamab Vedotin
also known as
BA3021 · CAB-ROR2-ADC · Cab-ror2-adc (ba-3021) · Ozuriftamab vedotina · Ozuriftamab vedotine
targets ROR2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03504488 | Jun 2018 → Dec 2024 | head and neck cancer, melanoma, non-small cell lung carcinoma, triple-negative breast carcinoma | BioAtla, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05271604 | Dec 2022 → Sep 2025 | head and neck squamous cell carcinoma, metastatic malignant neoplasm | BioAtla, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04918186 | May 2022 → Dec 2026 expected | ovarian cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ozuriftamab Vedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05271604 ↗ |
| Known as | BA3021 | “This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3021, a conditionally active...” NCT03504488 ↗2“A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck” NCT05271604 ↗ |
| Known as | CAB-ROR2-ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03504488 ↗ |
| Known as | Cab-ror2-adc (ba-3021) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095285 ↗ |
| Known as | Ozuriftamab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095285 ↗ |
| Known as | Ozuriftamab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095285 ↗ |
| Target | ROR2 | “Conditionally active biologic anti-ROR2 antibody drug conjugate” NCT03504488 ↗ |